TLDR
- BIAF stock surged over 55% on Tuesday after the company announced a new potential use for its CyPath Lung test in lung cancer survivors
- The company is exploring CyPath Lung for detecting cancer recurrence in patients who have completed curative-intent treatment
- Over 680,000 Americans were living with a prior lung cancer diagnosis as of January 1, 2025
- Trading volume exceeded 17 million, well above the 3-month average of 5.91 million
- AI analyst Spark rates BIAF as Underperform with a $5.50 price target, citing cash burn and revenue decline
BioAffinity Technologies stock was trading up more than 55% on Tuesday after the company put out a press release announcing it is advancing CyPath Lung for use in lung cancer survivors.
bioAffinity Technologies, Inc., BIAF
The stock opened the day already elevated, having climbed 65.57% in premarket trading. That followed a 6.37% drop the session before. Year-to-date, BIAF is still down 74.24%, and has lost 95.72% over the past 12 months.
The company said it is exploring CyPath Lung as a tool for cancer recurrence surveillance in patients who have finished curative-intent treatment.
$BIAF bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors pic.twitter.com/Bn7iBuL0j2
— DekmarTrades (@DekmarTrades) September 1, 2026
According to the American Cancer Society, more than 680,000 Americans were living with a prior lung cancer diagnosis as of January 1, 2025. The National Cancer Institute estimates around 230,000 new cases will be diagnosed in 2026.
For patients who finish treatment, a new pulmonary nodule on a scan can create real uncertainty. CT imaging can detect nodules but cannot always tell doctors whether it is cancer, a new tumor, or benign changes from treatment such as scarring or inflammation.
CyPath Lung gives a binary result: “unlikely” or “likely” malignancy. That could help physicians decide who needs further investigation and who can stay on routine monitoring.
Published studies put the recurrence rate for non-small cell lung cancer at between 20% and 55%, depending on stage and treatment type. The American Society of Clinical Oncology recommends surveillance imaging every six months for two years after curative-intent treatment of stage I to III NSCLC.
CyPath Lung’s Track Record
The test uses flow cytometry and proprietary AI to analyze cell populations in patient sputum. In a published clinical trial, it showed 92% sensitivity, 87% specificity, 88% accuracy, and a 99% negative predictive value in detecting early-stage lung cancer in high-risk patients.
BioAffinity said three years of commercial experience have shown the test can help doctors assess malignancy risk and guide patient decisions, including cases where imaging and predictive models produced conflicting results.
CEO Maria Zannes said the company believes surveillance after treatment “has the potential to lead to earlier intervention” and could work alongside early detection tools.
Oncologist Vijay Gunuganti, MD, of Texas Oncology said CyPath Lung “can provide additional information without immediately subjecting the patient to an invasive procedure.”
Chief Medical Officer Gordon Downie, MD, PhD, added that finishing treatment is “not the end of cancer care,” pointing to the growing importance of survivorship monitoring.
Volume and Analyst View
Trading volume on Tuesday hit more than 17 million, compared to a three-month daily average of about 5.91 million. That kind of volume spike usually reflects a fast-moving retail crowd responding to the news.
CyPath Lung is marketed as a Laboratory Developed Test and is not cleared as a standalone diagnostic tool. The clinical performance data cited relates to the detection setting and has not been separately validated for post-treatment surveillance.
AI analyst Spark rates BIAF as Underperform with a $5.50 price target, citing critical cash burn, deteriorating revenue, and a Nasdaq delisting threat as key risks.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
